HbA1c 血脂 UMA 对糖尿病肾病的影响分析

目的：探讨糖化血红蛋白（HbA1c）、血脂、尿微量白蛋白（UMA）对糖尿病肾病的影响。方法收集近年我院糖尿病的患者，定义为研究组，根据研究组 HbA1c 值分为低水平组（HbA1c<10%）、高水平组（HbA1c≥10%）。对照组为同期无高血压、冠心病、糖尿病的健康人群。对比研究组和对照组血脂、HbA1c、UMA水平。低水平组和高水平组血脂、HbA1c、UMA 水平。结果研究组和对照组生化指标和 UMA 水平比较有统计学差异（P<0.05）。低水平组和高水平组生化指标和 UMA 水平比较有统计学差异（P<0.05）。结论糖尿病肾病的发生发展与 HbA1c、血脂水平密切相关，UMA 可灵敏反映糖尿病早期肾脏损害。

HCY、CF-6、UMA水平与冠心病并心力衰竭的相关性分析

目的:对HCY、CF-6、UMA水平与冠心病并心力衰竭的相关性进行分析.方法:将我院心内科2015年1月至2017年1月间收治的200例冠心病并心力衰竭患者作为研究组,另取同期于我院检查的100例健康体检者作为对照组,分别测定两组人员HCY、CF-6、UMA水平,并进行对比.结果:研究组HCY、CF-6及UMA水平均要高于对照组,两组比较差异具有统计学意义(P<0.05).结论:HCY、CF-6、UMA水平与冠心病并心力衰竭存在密切联系,相对于健康群体,冠心病并心力衰竭患者HCY、CF-6、UMA水平明显更高,三者能够作为病情判断的依据,有利于预后评估.

3种指标在冠心病合并心力衰竭诊治中的应用及相关性研究

目的 观察血清同型半胱氨酸(HCY)、线粒体偶联因子6(CF-6)、尿微量蛋白(UMA)水平在冠心病合并心力衰竭患者诊治中的应用效果及相关性.方法 选取2012年6月至2016年6月河北省唐山市工人医院分院收治冠心痛合并心力衰竭患者200例,设为观察组;患者行常规方法治疗,根据治疗效果分为有效组(n=168)和无效组(n=32);取同期入院治疗的单纯冠心痛、心力衰竭患者各100名,设为冠心病组和心力衰竭组;同时,取同期入院健康体检者100例,设为健康对照组.采用循环酶法检测血清HCY水平,采用放射免疫分析法检测血清CF-6水平,采用免疫散射比浊法检测尿液UMA水平,分析HCY、CF-6、UMA水平在冠心痛合并心力衰竭患者诊治效果.结果 观察组、冠心痛组、心力衰竭组HCY、CF-6、UMA水平显著高于健康对照组,且差异具有统计学意义(P＜0.05),冠心病组与心力衰竭组HCY、CF-6、UMA水平比较差异无统计学意义(P＞0.05);观察组HCY、CF-6、UMA水平显著高于冠心病组和心力衰竭组,且差异具有统计学意义(P＜0.05);有效组和无效组HCY、CF-6、UMA水平均高于健康对照组,且差异具有统计学意义(P＜0.05);有效组HCY、CF-6、UMA水平,低于无效组,且差异具有统计学意义(P＜0.05);冠心病合并心力衰竭发生率与HCY、CF-6、UMA水平呈正相关性(P＜0.05).结论 冠心病合并心力衰竭患者血清HCY、CF-6、UMA水平检测在疗效观察中有一定的作用.

血清胱抑素C和尿微量白蛋白在老年2型糖尿病早期肾功能损害监测中的临床研究

目的 了解血清胱抑素c和尿微量白蛋白在老年糖尿病患者早期肾功能损害监测中的临床意义.方法 我们以2008-07-2009-08在我院就诊或住院的老年2型糖尿病患者46例为患者组,40例无糖尿痛及肾病的健康老年人作为对照组,测定BUN、Scr、Ucr、UMA、Scys C和血压并用Scr、Ucr、体表面积和24h尿量计算出CCr,将结果 作统计学处理.结果 患者组的BUN、Scr、UMA、Scys C和CCr均值均显著高于对照组,(P均＜0.01),患者组的Scys C、CCr和UMA异常例数分别为32例(69.56%)、32例(69.56%)和30例(65.22%),高于Scr,在Scr正常者中Scys C和CCr亦有异常,分别为9例(39.13%)和9例(39.13%).结论 Scys C和CCr对老年糖尿痛患者早期肾功能损害有指导意义,但以Scys C临床适用性较好,UMA可作为糖尿病肾病早期诊断的参考指标.

Objective:To observe the effect of atorvastatin combined with ezetimibe on the levels of urine protein, PCT, serum lipid, and hs-CRP in patients with acute coronary syndrome (ACS). Methods:A total of 90 ACS patients who were admitted in our hospital were included in the study and randomized into A, B, and C groups with 30 cases in each group. The patients in A group were given atorvastatin (20 mg/d, a maintenance dose), the patients in B group were given atorvastatin (40 mg/d, a load dose), while the patients in C group were given atorvastatin in a load dose combined with ezetimibe (10 mg/d). The changes of 24 h UMA, PCT, serum lipid, and hs-CRP after two-week treatment in the three groups were observed, and the adverse reactions in the three groups were observed.Results:The improvements of urine protein, PCT, and serum hs-CRP concentration after treatment in B and C groups were significantly superior to those in A group (P<0.05). The improvements of urine protein, PCT, and serum hs-CRP concentration after treatment in C group were significantly superior to those in A and B groups (P<0.05). The levels of TC and LDL-C after treatment in B and C groups were significantly reduced when compared with those before treatment (P<0.05). The levels of TC and LDL-C after treatment in group A were not statistically different from those before treatment (P>0.05). No obviously adverse reactions occurred in the three groups.Conclusions:Atorvastatin in a load dose combined with ezetimibe can significantly adjust the levels of UMA, PCT, and serum lipid in ACS patients, reduce the concentrations of inflammatory factors, and play an active role in the treatment of ACS.